FINSMES – Omicia, Inc., an Oakland, CA-based provider of clinical genome interpretation and reporting software, completed a $23m Series B financing round.
Backers included new investors UPMC Enterprises, Roche Venture Fund, LDV Partners, Ping An Ventures, and a large genomics investor, as well as existing investors ARTIS Ventures, Acadia Woods Partners and Buchanan Investments.
The company intends to use the funds to accelerate product development, expansion in sales, sales support, marketing and operations, and extend variations of its flagship OpalTM Clinical platform for use in new geographies and new verticals including life science research, clinical trial support, population health management and consumer applications.
A (Dog’s) Day in the Life: Work from Home Edition
My name is Denali. I’m one of the regular Doggie Day “coworkers” at UPMC Enterprises. However, it has been a couple months since my mom started working from home full-time.
Meet the Executive: David Gibson, Chief Financial Officer of UPMC Enterprises
David Gibson was named Chief Financial Officer of UPMC Enterprises in November 2019. As CFO, …